XML 37 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net loss $ (27,017) $ (27,916) $ (29,537)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 59 76 81
Loss (gain) on retirement/sales of property and equipment   5 (16)
Accretion and amortization on investments, net (978) 273 552
Change in fair value of equity investment, including foreign currency translation 604    
Stock-based compensation for services by non-employees 191 200 156
Stock-based compensation for employees and directors 6,368 8,144 8,245
Amortization related to 401(k) contributions 9 32 61
Changes in assets and liabilities:      
Interest and other receivables (528) 39 731
Prepaid assets (752) (56) 123
Accounts payable 479 278 65
Accrued compensation and benefits (743) 542 (183)
Amount due to Janssen Biotech, Inc. 908 (1,665) 1,039
Accrued liabilities 391 (508) 314
Net cash used in operating activities (21,009) (20,556) (18,369)
Cash flows from investing activities:      
Purchases of property and equipment (16)   (57)
Proceeds from sales of property and equipment     16
Purchases of marketable securities (188,365) (100,006) (129,250)
Proceeds from maturities of marketable securities 110,663 122,976 138,054
Net cash (used in) provided by investing activities (77,718) 22,970 8,763
Cash flows from financing activities:      
Proceeds from issuances of common stock under equity plans 6,951 51 1,169
Proceeds from issuances of common stock from financings 86,017 1,060  
Net cash provided by financing activities 92,968 1,111 1,169
Net (decrease) increase in cash, cash equivalents and restricted cash (5,759) 3,525 (8,437)
Cash, cash equivalents and restricted cash at the beginning of the period 16,603 13,078 21,515
Cash, cash equivalents and restricted cash at the end of the period $ 10,844 $ 16,603 $ 13,078